Pet Pharm Biotech Co (ROCO:7762) Revenue: NT$265.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
26 GF Score
Price NT$60.10
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Revenue?

Pet Pharm Biotech Co ROCO:7762 +3.80% 26 Revenue is NT$265.5 Mil as of Jun. 2026. GuruFocus rates ROCO:7762 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

Pet Pharm Biotech Co's revenue for the six months ended in Jun. 2026 was NT$127.8 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$265.5 Mil. Pet Pharm Biotech Co's Revenue per Share for the six months ended in Jun. 2026 was NT$2.20. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$4.57.

During the past 12 months, the average Revenue per Share Growth Rate of Pet Pharm Biotech Co was 34.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Pet Pharm Biotech Co's highest 3-Year average Revenue per Share Growth Rate was 11.40% per year. The lowest was 11.40% per year. And the median was 11.40% per year.

Pet Pharm Biotech Co  (ROCO:7762) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Pet Pharm Biotech Co Revenue Related Terms

Pet Pharm Biotech Co Revenue Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Revenue Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
75.74 117.87 130.70 222.03

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Revenue Get a 7-Day Free Trial 55.94 74.76 84.26 137.77 127.77

ROCO:7762 vs LLY, JNJ, ABBV: Revenue Comparison

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pet Pharm Biotech Co Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Revenue distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's Revenue falls into.


ROCO:7762
26GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$265.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of NT$265.5 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Revenue of NT$265.5 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Revenue too high?
Pet Pharm Biotech Co's current Revenue is NT$265.5 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Revenue compare to LLY and JNJ?
Pet Pharm Biotech Co's Revenue of NT$265.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Revenue is NT$265.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Revenue of NT$265.5 Mil. The current Revenue is NT$265.5 Mil. Pet Pharm Biotech Co's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Revenue is NT$265.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
26GF Score

Get the complete analysis for ROCO:7762

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$60.10
Price